Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Advances in the treatment of acute myeloid leukemia: new drugs and new challenges
NJ Short, M Konopleva, TM Kadia, G Borthakur… - Cancer discovery, 2020 - AACR
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …
the past few years, driven largely by translational research into its genomic landscape and …
[HTML][HTML] Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …
[HTML][HTML] Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …
[HTML][HTML] Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
Abstract Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …
Uncovering expression signatures of synergistic drug responses via ensembles of explainable machine-learning models
Abstract Machine learning may aid the choice of optimal combinations of anticancer drugs
by explaining the molecular basis of their synergy. By combining accurate models with …
by explaining the molecular basis of their synergy. By combining accurate models with …
[HTML][HTML] Venetoclax resistance: mechanistic insights and future strategies
F Ong, K Kim, MY Konopleva - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
D Thomalla, L Beckmann, C Grimm… - Blood, The Journal …, 2022 - ashpublications.org
The BCL2 inhibitor venetoclax has been approved to treat different hematological
malignancies. Because there is no common genetic alteration causing resistance to …
malignancies. Because there is no common genetic alteration causing resistance to …
Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy
S Venugopal, M Shoukier, M Konopleva, CD Dinardo… - Cancer, 2021 - Wiley Online Library
Background Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has
become the standard of care for patients aged> 75 years and for those not eligible for …
become the standard of care for patients aged> 75 years and for those not eligible for …
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
G Richard-Carpentier… - Therapeutic advances in …, 2019 - journals.sagepub.com
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally
poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently …
poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently …